NTLA - インテリア・セラピュ―ティクス （Intellia Therapeutics Inc.） インテリア・セラピュ―ティクスNTLAのチャート
NTLAの企業情報
| symbol | NTLA |
|---|---|
| 会社名 | Intellia Therapeutics Inc （インテリア・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: In Vitro_In Vivo Diagnostic Substances |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 インテリア・セラピューティクス(Intellia Therapeutics Inc.)はゲノム編集会社である。同社はCRISPR/Cas9という生物学的ツールを利用した治療法の開発に従事する。CRISPR/Cas9ゲノム編集システムは2つの成分を含む。Cas9タンパク質は遺伝子のノックアウト・修復・挿入のための自然細胞修復プロセスを開始する分子ハサミのように働く。ガイドRNA配列はCas9を特定の標的デオキシリボ核酸（DNA）配列に認識し導く。同社のセンチネルインビボプログラムは、肝臓へのCRISPR/Cas9複合体の送達のための脂質ナノ粒子（LNP）の使用に焦点を当てる。同社の事業部であるeXtellia Therapeuticsは、免疫腫瘍学・自己免疫性疾患・炎症性疾患の分野におけるCRISPR / Cas9ゲノム編集の応用に従事する。同社の子会社はIntellia Securities Corpを含む。 インテリア・セラピュ―ティクスは米国のライフサイエンス企業。遺伝子改変技術に取り組み、ゲノム編集ツ―ルである「クリスパ―・キャス9(CRISPR/Cas9)」システムを利用し、トランスチレチン・アミロイド症やB型肝炎、アンチトリプシン欠乏症などの治療を可能にする。本社はマサチュ―セッツ州ケンブリッジ。 Intellia Therapeutics is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products. |
| 本社所在地 | 40 Erie Street Suite 130 Cambridge MA 02139 USA |
| 代表者氏名 | Perry A. Karsen ペリーA.カーセン |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 857-285-6200 |
| 設立年月日 | 41760 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2016年 |
| 従業員数 | 195人 |
| url | www.intelliatx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ntla |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -82.90700 |
| 終値（lastsale） | 24.21 |
| 時価総額（marketcap） | 1045887324.93 |
| 時価総額 | 時価総額（百万ドル） 958.62210 |
| 売上高 | 売上高（百万ドル） 29.13100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 653.08410 |
| 当期純利益 | 当期純利益（百万ドル） -82.89400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Intellia Therapeutics Inc revenues increased 25% to $15.1M. Net loss increased 54% to $43.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research_Development - Balancing value increase of 58% to $40.9M (expense) Stock-based Compensation in R&D increase of 64% to $5M (expense). |
NTLAのテクニカル分析
NTLAのニュース
BMO Capital downgrades Intellia Therapeutics Inc to Market Perform with a price target of $64.00 2023/05/05 07:08:37 Investing.com
https://www.investing.com/news/pro/intellia-therapeutics-inc-receives-investment-bank-analyst-rating-update-3073986
Why Intellia Therapeutics Shares Are Surging Today 2023/05/04 18:10:43 Benzinga
Intellia Therapeutics, Inc. (NASDAQ: NTLA ) shares are up Thursday as its Q1 results surpassed estimates. The company looks forward to sharing new interim data from NTLA-2001 and NTLA-2002 first-in-human studies in the coming months. NTLA reported first-quarter FY23 collaboration revenue of $12.61 million, up 12% year over year, beating the analyst consensus of $11.83 million . The … Full story available on Benzinga.com
Intellia jumps 13% after Q1 updates 2023/05/04 17:43:10 Seeking Alpha
Intellia Therapeutics (NTLA) added ~13% on Thursday after the gene-editing company reported its Q1 2023 financials alongside updates from its pipeline. Read more here.
Intellia Therapeutics, Inc. (NTLA) Q1 2023 Earnings Call Transcript 2023/05/04 16:08:12 Seeking Alpha
Intellia Therapeutics, Inc. (NASDAQ:NASDAQ:NTLA) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ETCompany ParticipantsIan Karp - Senior Vice President, Investor Relations and…
Intellia Therapeutics, Inc. 2023 Q1 - Results - Earnings Call Presentation 2023/05/04 11:51:34 Seeking Alpha
The following slide deck was published by Intellia Therapeutics, Inc.
Results from Intellia Therapeutics Inc. (NTLA) show risk 2023/03/08 12:40:00 US Post News
As of Tuesday, Intellia Therapeutics Inc.’s (NASDAQ:NTLA) stock closed at $40.03, down from $40.08 the previous day. While Intellia Therapeutics Inc. has underperformed by -0.14%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NTLA fell by -38.46%, with highs and lows ranging from $78.58 to $32.44, […]
“Strong Buy” Intellia Therapeutics Stock (NASDAQ:NTLA) Still Requires Prudence 2023/03/08 03:04:00 TipRanks
Aside from artificial intelligence (AI) and cryptocurrencies, a longtime hot stock on Wall Street revolves around gene editing research and develop…
Intellia Therapeutics: Progressing Pipeline Signals Positive Outlook (NTLA) 2023/03/08 02:06:28 Seeking Alpha
Intellia is well-positioned to capitalize on the growing demand for gene editing therapies. Click here to learn more about what makes NTLA stock a Buy.
7 Cathie Wood Stocks for Your March Buy List 2023/03/07 19:48:57 InvestorPlace
Investing in Cathie Wood stocks means directing your money toward innovation. And that means investing heavily in tech, a sector that has been pummeled by interest rates held higher by a Federal Reserve battling runaway inflation. Cathie Wood’s portfolio can be found here and includes hundreds of holdings primarily in tech. Wood’s ARK Investment Management includes several actively managed ETFs that focus on high-growth companies in fields such as genomics, robotics, and fintech. ARK’s most popular funds include the ARK Innovation ETF (NYSEARCA: ARKK ), ARK Next Generation Internet ETF (NYSEARCA: ARKW ), and ARK Genomic Revolution ETF (BATS: ARKG ). Of course, any investor seeking to invest in Cathie Wood stocks could simply establish a position in any of those ETFs. That would be a reasonable method for following her investment methods. However, this list consists of individual stock picks all found within ARK’s respective ETFs. NVDA Nvidia $234.27 TSLA Tesla $189.67 NTLA Intellia Therapeutics $40.51 ADYEY Adyen $14.43 CAT Caterpillar $248.26 CRSP CRISPR $48.18 MGA Magna International $55.59 Cathie Wood Stocks: Nvidia (NVDA) Source: Michael Vi / Shutterstock.com Most investors know Nvidia (NASDAQ: NVDA ) as a leading semiconductor company that designs and manufactures advanced graphics processing units for gaming, data centers, and artificial intelligence.
Why Is Intellia Therapeutics (NTLA) Stock Up 10% Today? 2023/03/02 20:18:06 InvestorPlace
Amid yet another soft session on Wall Street, biotechnology firm Intellia Therapeutics (NASDAQ: NTLA ) brightened the room considerably. Receiving a regulatory green light from the Food and Drug Administration (FDA), Intellia can now begin testing its CRISPR gene-editing technology in human patients. Naturally, NTLA stock jumped on the implications, initially popping up 10%. However, prospective investors should also recognize certain risk factors. CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats , represents “…the hallmark of a bacterial defense system that forms the basis for CRISPR-Cas9 genome editing technology,” according to the Broad institute. Scientists note that this innovation underlies a faster, cheaper and more accurate process of DNA editing than previous techniques. Specifically for NTLA stock, the FDA’s go-ahead to Intellia represents the first domestic test of an in-vivo gene-editing drug. According to Investor’s Business Daily , “With this approach, the genetic edit takes place inside the body.
Why Is Intellia Therapeutics (NTLA) Stock Up 10% Today? 2023/03/02 20:18:06 InvestorPlace
Amid yet another soft session on Wall Street, biotechnology firm Intellia Therapeutics (NASDAQ: NTLA ) brightened the room considerably. Receiving a regulatory green light from the Food and Drug Administration (FDA), Intellia can now begin testing its CRISPR gene-editing technology in human patients. Naturally, NTLA stock jumped on the implications, initially popping up 10%. However, prospective investors should also recognize certain risk factors. CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats , represents “…the hallmark of a bacterial defense system that forms the basis for CRISPR-Cas9 genome editing technology,” according to the Broad institute. Scientists note that this innovation underlies a faster, cheaper and more accurate process of DNA editing than previous techniques. Specifically for NTLA stock, the FDA’s go-ahead to Intellia represents the first domestic test of an in-vivo gene-editing drug. According to Investor’s Business Daily , “With this approach, the genetic edit takes place inside the body.
Why Intellia Therapeutics Stock Jumped This Week 2023/03/02 19:12:00 The Motley Fool
Intellia Therapeutics landed a historic regulatory nod from the FDA.
Hot Stocks: OKTA, KR rise on earnings news; PLUG drops; NTLA climbs as FDA clears trial 2023/03/02 17:55:31 Seeking Alpha
OKTA and KR climbed on earnings news. PLUG fell after its quarterly update. NTLA rose after receiving FDA clearance for a clinical trial.
Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing 2023/03/02 14:24:50 Investor''s Business Daily
The FDA cleared Intellia to begin testing its CRISPR gene-editing technology in people on Thursday, leading NTLA stock to jump.
: Intellia’s stock jumps as CRISPR therapy moves into Phase 2 clinical trial 2023/03/02 13:09:00 MarketWatch
Shares of Intellia Therapeutics Inc. NTLA rallied about 10% in premarket trading on Thursday after the company said the Food and Drug Administration will allow its experimental CRISPR therapy to move into the Phase 2 part of the Phase 1/2 clinical trial. The single-dose therapy is being assessed as a treatment for hereditary angioedema, a rare disorder that causes severe swelling. Intellia plans to share data from the Phase 1 part of the study later this year. The company’s stock is up 16.8% so far this year, while the broader S&P 500 SPX has gained 3.2%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.